GIMAP5 and lung adenocarcinoma: By combining molecular biomarkers (CST1 and GIMAP1-GIMAP5), clinical data, and CT characteristics, this tool offers a personalized risk stratification approach to guide decisions on surveillance, biopsy, or intervention, potentially minimizing unnecessary procedures and improving timely management of lung adenocarcinoma in pandemic contexts.